Adnan Butt, RBC: Hi Lori is there you can be a bit more specific about what we might expect at ASCO at this time and secondly when could we get greater clarity other phase 3I trials likely will be pursued this year or is it more likely to be next year.
Lori Kunkel: So your second question is that we certainly expect to give you more clarity around the other two trials by the end of the year and hopefully around mid-year and we gave you clarity on our first trial which we committed to about mid year and our second trial we are going to moving forward with discussion in front line elderly. Also, with respect to ASCO, wewill presenting data on the bendamustine and rituxan combination with ibrutinib as well as the first cohort on the ofatumumab ibrutinib combination and we will be presenting our first analysis on our single agent activity in the frontline elderly. So, if you take an overarching look on how these trials are rolling out again strategy of relapsed as single agent as well as in combination and to move upfrontvery quickly.
I believe we are just getting stared..IMO. Stay long my friends.